144 related articles for article (PubMed ID: 33471679)
1. Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women.
Sofer Y; Yaish I; Yaron M; Bach MY; Stern N; Greenman Y
Endocr Pract; 2020 Aug; 26(8):883-890. PubMed ID: 33471679
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
[TBL] [Abstract][Full Text] [Related]
3. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
[TBL] [Abstract][Full Text] [Related]
5. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
[TBL] [Abstract][Full Text] [Related]
6. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
Liang JJ; Jolly D; Chan KJ; Safer JD
Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822
[TBL] [Abstract][Full Text] [Related]
7. PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE.
Bisson JR; Chan KJ; Safer JD
Endocr Pract; 2018 Jul; 24(7):646-651. PubMed ID: 29708436
[TBL] [Abstract][Full Text] [Related]
8. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J
Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
[TBL] [Abstract][Full Text] [Related]
9. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
[TBL] [Abstract][Full Text] [Related]
10. Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang C; Yeung KK
Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
[TBL] [Abstract][Full Text] [Related]
11. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
[TBL] [Abstract][Full Text] [Related]
12. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
14. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
[TBL] [Abstract][Full Text] [Related]
15. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.
Collet S; Gieles NC; Wiepjes CM; Heijboer AC; Reyns T; Fiers T; Lapauw B; den Heijer M; T'Sjoen G
J Clin Endocrinol Metab; 2023 Jan; 108(2):331-338. PubMed ID: 36201493
[TBL] [Abstract][Full Text] [Related]
16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
18. Effects of cross-sex hormone treatment on transgender women and men.
Deutsch MB; Bhakri V; Kubicek K
Obstet Gynecol; 2015 Mar; 125(3):605-610. PubMed ID: 25730222
[TBL] [Abstract][Full Text] [Related]
19. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.
Gava G; Cerpolini S; Martelli V; Battista G; Seracchioli R; Meriggiola MC
Clin Endocrinol (Oxf); 2016 Aug; 85(2):239-46. PubMed ID: 26932202
[TBL] [Abstract][Full Text] [Related]
20. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer.
Rost A; Schmidt-Gollwitzer M; Hantelmann W; Brosig W
Prostate; 1981; 2(3):315-22. PubMed ID: 6458025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
